Colorectal cancer is a major cause of morbidity and mortality accounting for an estimated
550,000 deaths annually worldwide. Colonic neoplasia develops in a stepwise fashion …

In addition to the well-established pathophysiological role that COX-2 plays in inflammation,
recent evidence implies that this isoform may also be involved in multiple biologic events …

Despite recent improvements in chemotherapy and radiation therapy in cancer management
with the addition of biological agents, novel treatment approaches are needed to further …

Several lines of evidence suggest that cyclooxygenase-2 (COX-2) is a rational target for
anticancer therapy. Epidemiological studies have shown that use of nonsteroidal anti …

COX-2 is upregulated at an early stage in colorectal carcinogenesis and generates
prostaglandins, which promote cancer cell proliferation, impair apoptosis and enhance …

Multiple lines of evidence suggest that aberrant induction and upregulation of the
prostaglandin cascade play a significant role in colon and mammary carcinogenesis, and …

The discovery of the isoenzymes cyclooxygenase (COX-) 1 and COX-2 led to the
development of newer nonsteroidal anti-inflammatory drugs (NSAIDs) designed to block …

Prostaglandin synthesis by a number of enzymes is important at all stages during the
genesis of cancer. The availability of prostaglandin H2 as a substrate for prostaglandin …

Cyclooxygenase (COX), a key enzyme in the prostanoid biosynthetic pathway, has received
considerable attention due to its role in human cancers. Observational and randomized …

Several lines of evidence suggest that the cyclooxygenase enzymes (specifically COX-2)
might be an important molecular target for the intervention of cancer at both early and late …